Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Prepaid Assets data on record, last reported at $514910.0 in Q1 2026.

  • On a quarterly basis, Prepaid Assets rose 881.25% to $514910.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $514910.0, a 881.25% increase, with the full-year FY2025 number at $1.0 million, up 21.24% from a year prior.
  • Prepaid Assets reached $514910.0 in Q1 2026 per IKT's latest filing, down from $1.0 million in the prior quarter.
  • Over the last five years, Prepaid Assets for IKT hit a ceiling of $1.2 million in Q1 2022 and a floor of $52475.0 in Q1 2025.
  • A 5-year average of $672245.3 and a median of $739179.0 in 2023 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: skyrocketed 944.5% in 2022, then plummeted 93.83% in 2025.
  • Tracing IKT's Prepaid Assets over 5 years: stood at $1.1 million in 2022, then tumbled by 33.86% to $739179.0 in 2023, then increased by 11.81% to $826473.0 in 2024, then increased by 21.24% to $1.0 million in 2025, then plummeted by 48.61% to $514910.0 in 2026.
  • Business Quant data shows Prepaid Assets for IKT at $514910.0 in Q1 2026, $1.0 million in Q4 2025, and $618783.0 in Q3 2025.